AI
HRMY icon

Atom Investors’s Harmony Biosciences HRMY Stock Holding History

Atom Investors’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-79,345
Closed -$2.87M – 326
2020
Q4 		$2.87M Buy
+79,345
New +$3.2M 0.29% 92

Other funds holding HRMY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
NP
Newlight Partners New York $3.9M AUM 96.05% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Atom Investors's HRMY Position: Q1 2021 in Review

Atom Investors sold out of Harmony Biosciences (HRMY) in Q1 2021, closing a stake of 79,345 shares — an estimated $2.87M sold.

Atom Investors first reported a position in HRMY in Q4 2020 and held it in 1 quarter. The position peaked at $2.87M in Q4 2020. 57 funds tracked by Wall St. Rank hold HRMY as of Q1 2021.

  • Atom Investors reported no remaining Harmony Biosciences position as of Q1 2021 after selling out during the quarter.
  • Atom Investors sold 79,345 Harmony Biosciences shares in Q1 2021, an estimated $2.87M.
  • Atom Investors first reported a position in Harmony Biosciences in Q4 2020 and held it in 1 quarter.
  • Atom Investors's Harmony Biosciences position peaked at $2.87M in Q4 2020.
  • 57 funds tracked by Wall St. Rank held Harmony Biosciences as of Q1 2021.

Based on Atom Investors's 13F filing for Q1 2021, filed 17 May 2021.